ABBV AbbVie Inc.
Company Analysis
Latest News
AbbVie Nears $10.9 Billion Apogee Deal, Strengthening Immunology Pipeline
AbbVie is nearing a $10.9 billion cash agreement to acquire Apogee Therapeutics. The proposed deal values the clinical-stage biotech at a 60% premium over its...
AbbVie Unveils Venclexta and Epcoritamab Data, Bolstering Oncology Market Position
AbbVie is presenting new blood cancer portfolio data at the European Hematology Association (EHA) 2026 Congress. Presentations include updates on approved and...
🟢 AbbVie Inc. shares rise 3.6% after its cancer drug Elahere wins NHS approval in England
AbbVie Inc. is trading at $225.00 (+3.6%) in pre-market after its ovarian cancer drug, Elahere, was approved for use by the NHS in England. • The approval...
🟢 AbbVie Inc. is trading 3% up today as shares extend a multi-day rebound amid a rotation into defensive healthcare
AbbVie Inc. is trading 3% up at $223.65, extending its recent multi-day rebound from last week’s pullback despite a lack of fresh company-specific...
AbbVie's Venclyxto Wins Expanded EU Approval for First-Line Leukemia Treatment
On May 29, 2026, AbbVie received European Commission authorization. This expands the label for its cancer drug, VENCLYXTO (venetoclax). The approval covers the...
AbbVie secures EU approval for Aquipta, offering dual-action migraine relief
AbbVie received European Commission approval for Aquipta (atogepant) on June 2, 2026. This authorization covers the acute treatment of migraine with or without...
AbbVie's first quarter 2026 revenue of $15.0B beat estimates, driven by strong Skyrizi and Rinvoq sales.
AbbVie reported first quarter 2026 revenue of $15.002 billion, a 12.4% year-over-year increase that surpassed analyst expectations of $14.78 billion. Adjusted...
AbbVie Inc Q1 2026 Earnings Preview: What Analysts Expect on April 29, 2026
AbbVie is expected to report Q1 2026 revenue of $14.78 billion and adjusted EPS of $2.69, with the stock currently trading at $198.71 against an average...
AbbVie and Regeneron Remain in Drug Pricing Talks as Johnson & Johnson Reaches Deal with U.S. Government
AbbVie Inc. remains in discussions with the White House over drug pricing, according to a Bloomberg report. The company is one of only two major pharmaceutical...
AbbVie Denies Revolution Medicines Acquisition Talks, Impacting Stock
AbbVie (ABBV) shares declined 3.98% after the company publicly denied being in advanced talks to acquire cancer-drug developer Revolution Medicines. The...
AbbVie Downgraded by Wolfe Research on Limited Upside Concerns
Wolfe Research downgraded AbbVie (ABBV) to 'Peer Perform.' The firm cited the company's strong performance over the last two years, arguing it leaves limited...
🔴 AbbVie is trading 3.3% down today after recent dividend-hike rally
ABBV is trading 3.3% down at $225.81, experiencing a pullback and profit-taking following a sharp multi-day run-up that saw the stock climb above $230. * No...
AbbVie lowers Q4 and FY25 EPS guidance due to a $1.3 billion R&D expense.
AbbVie updated its Q4 and full-year 2025 earnings guidance to reflect a significant expense related to acquired in-process research and development (IPR&D)....
AbbVie Reportedly in Advanced Talks to Acquire Oncology Firm Revolution Medicines
AbbVie is in advanced discussions to acquire Revolution Medicines, according to a report from The Wall Street Journal. Revolution Medicines specializes in...
🟢 ABBV is trading 3.65% up today after UBS price target hike
ABBV is trading at $232.10 (+3.65%), following UBS raising its price target to $240 from $220. * The stock builds on yesterday's close of $223.93 (+1.70%)...
AbbVie Bolsters Oncology Pipeline with Over $1.1B Lung Cancer Drug Deal
AbbVie Inc. significantly expanded its oncology pipeline by securing ex-China rights to Zejing Biopharmaceutical's late-stage lung cancer drug, ZG006...
AbbVie Stock Declines Nearly 4% Following Recent Strategic and Financial Updates
AbbVie's stock decreased 3.98% on the previous trading day, closing at $220.18. This movement follows a series of recent company developments and strategic...
🔴 ABBV is trading 4.7% down today
ABBV is trading at $218.60 (-4.67%), diverging sharply from broader market gains as no specific news or event explains the sudden decline. The decline...
🔴 ABBV is trading 4% down today
ABBV is trading at -4.02% now at $220.09 as the stock experiences an unexplained drop ahead of a routine J.P. Morgan Healthcare Conference presentation. * ...
🔴 ABBV is trading 4% down today
ABBV is trading at $220.09 (-4.02%), experiencing a significant drop without clear company-specific catalysts or news identified for the session. * The...